Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
Original-Research

NFON AG (von NuWays AG): BUY 20.11.2026, 09:01 Uhr von EQS Research Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
NFON 3,475 EUR +5,30 % Lang & Schwarz
Kostenlose Aktienchance per SMS Ausgewählte Trading-Einschätzungen aufs Handy.

Original-Research: NFON AG - from NuWays AG

20.11.2026 / 09:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to NFON AG

Company Name: NFON AG
ISIN: DE000A0N4N52
 
Reason for the research: Update
Recommendation: BUY
Target price: EUR 5
Target price on sight of: 12 months
Last rating change:
Analyst: Philipp Sennewald

Q3: decline slowing, margins recovering

Yesterday's Q3 came in line on sales but clearly beat our profitability estimates. More importantly, the new AI disclosure allows to quantify what it takes to return to growth. In detail:

Q3 sales of € 21.1m (-3.1% yoy, eNuW: € 21.1m) marked an improvement vs Q2’s -5.2%. Breaking it down, recurring revenues rose 2% qoq to € 20.2m despite c. 7.5k fewer seats, as ARPU jumped to € 10.19 (Q2: € 9.95, eNuW: € 10.03) on price adjustments and premium solutions. Seat losses also eased vs Q2 (c. 11.3k), with management confirming the portfolio clean-up to be largely done. Remaining qoq seat attrition of c. 1% is hence the run-rate to watch, with the UK (9M sales and seats down close to double digits) as the main drag.

Margin beat on cost control. Q3 adj. EBITDA rose 7.6% yoy to € 3.3m (eNuW: € 2.5m), implying a 15.5% margin (+1.5pp yoy) despite lower sales and a slightly weaker gross margin. The improvement came entirely from opex as personnel and other operating expenses combined fell € 1.2m yoy to € 14.9m in Q3. Part of this is variable, namely lower sales commissions on the reduced top line, but the bulk reflects the support restructuring and tighter spending on consulting and external services. In our view, it is therefore largely sustainable.

First time AI metric disclosure. Intelligent Assistant (€ 1.7m, +40% yoy, Q3: +74%) and Customer Engagement (€ 2.7m, +12%) now account for 7.3% of recurring revenues (9M’25: 5.8%). Annualised, this adds some € 1.5m p.a., only half of what PBX currently loses (c. € 3m). The way forward hence runs through the base. With the clean-up completed and a new UK team in place, we forecast a return to seat growth in FY27e, allowing AI growth to translate fully into group growth (eNuW: +1.7% yoy). This also widens the upsell opportunity, as AI embedded in PBX generates only c. € 0.6m so far. Key milestones are quarterly seat development and the FY27 guidance on 25 February.

Guidance looks achievable. Management confirmed its FY guidance of € 84.5-86.0m sales and € 9.5-10.5m adj. EBITDA. On sales, this implies Q4 revenues of € 20.9-22.4m, broadly in line with Q3’s € 21.1m and with our new FY26e of € 85.3m (Q4e: € 21.6m), which looks well covered given the slowing decline. On profitability, the guidance implies only € 1.8-2.8m adj. EBITDA in Q4, i.e. an 8.0-13.4% margin vs 15.5% in Q3. Simply repeating Q3 would put FY26 at c. € 11m, above the top end of the range. Even accounting for the one-off-heavy Q4'25 base, we see the mid-point as well within reach (new eNuW: € 10.0m).

Valuation prices in continued decline. Shares trade at 6.9x EV/adj. EBITDA FY26e, which we regard a deep discount for a 95% recurring, cash-generative business. While this clearly reflects the shrinking seat base and this year’s guidance cut, the Q3 results point in the right direction. A return to seat growth in FY27e should thus allow for a re-rating.

Reiterate BUY, unchanged € 5.00 PT based on DCF.

READ RESEARCH HERE



 

You can download the research here: Research_NuWays
For additional information visit our website: https://www.nuways-ag.com/research

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2439222  20.11.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer